Assessment of drug interaction potential between the direct-acting antiviral agents elbasvir/grazoprevir and integrase inhibitors raltegravir and dolutegravir | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Assessment of drug interaction potential between the direct-acting antiviral agents elbasvir/grazoprevir and integrase inhibitors raltegravir and dolutegravir

Feng HP, Guo Z, Ross L, et al. Assessment of drug interaction potential between the direct-acting antiviral agents elbasvir/grazoprevir and integrase inhibitors raltegravir and dolutegravir. J Antimicrob Chemother. 2019;74(3):710-717.

Publication Type:

Journal Article

Authors:

Feng, HP; Guo, Z; Ross, L; et, al

Source:

J Antimicrob Chemother, Volume 74, Issue 3, p.710-717 (2019)

Cited On:

Patients With HIV/HCV Coinfection

Export Citation:

RIS Format

Top